Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands

OSF Preprints (OSF Preprints) 2026 Preprint

Authors: Yansi Wu, Maureen Rutten‐van Mölken, Tom Belleman, Mirjana Huić, Sabine Vogler, Nina Zimmerman, Eli Feiring, Renaud J.S.D. Heine, Oliver Groene, Anne Hendrickx, Tomas Tesar, Ruslan David
+18 more Emily Annika Burger, Carin Uyl-de Groot, Frederick W.F. Thielen, Pia Sofie Henkel, Katia Roque Molina, N Xander, Marcel Langone Marques, Peter Schneider, Kate Morgan, Mauro Melli, Eline Aas, Benjamin P. Geisler, Isabelle Durand‐Zaleski, Katie Joyner, Robin Doeswijk, Maximilian Salcher‐Konrad, Lena Jessen, Gauthier Quinonez
Cited by: 0

Fields of Study & Subjects

Pharmaceutical Economics and Policy Health Systems Economic Evaluations Quality of Life Intellectual Property and Patents

Publication details

Journal / source
OSF Preprints (OSF Preprints)
Publication date
15 January 2026
Document type
Preprint